What does out of specification mean?
An out-of-specification, or OOS, result falls outside an established acceptance criterion. FDA uses this meaning in its pharmaceutical OOS guidance. See the May 2022 FDA guidance, introduction (PDF). The document concerns pharmaceutical testing; it is a reference for informed questions here, not evidence of regulatory status or compliance for our catalogue.
For your purchase, put the relevant result beside the exact requirement you agreed. Record the measurement, units, reporting basis and specification revision. If the quotation never defined a criterion, ask for clarification rather than inventing a pass limit after seeing the number.
This guide covers an unexpected analytical result. An incorrect carton count or artwork error belongs in a separate order-concern record, even when both issues affect the same delivery.
Keep the first result and the order reference together.
Create a short record your purchasing and technical reviewers can both follow. Preserve the received report version and the supplier's explanation. A later document should have a clear relationship to that history.
| Field | Record or request |
|---|---|
| Material and supply | Exact peptide identity, proposed lot and order reference |
| Requirement | Accepted specification revision, measurement and criterion |
| Initial result | Report version, sample reference, method, units and date |
| Investigation | Reference, responsible contact, status and next review date |
| Additional analysis | Purpose, sample relationship, reports and technical interpretation |
| Order decision | Reviewer, supporting records and written purchasing instruction |
The batch-traceability guide helps connect identifiers. The broader COA checklist covers the rest of the report review.
Ask what was investigated, not just what was repeated.
ICH Q7 section 11.15 calls for a documented investigation, data assessment, corrective-action responsibilities and conclusions when an OOS result occurs. It also addresses documented procedures for subsequent retesting or resampling. Read ICH Q7 section 11.15 (PDF). Q7 addresses active pharmaceutical ingredients; citing it does not classify these catalogue materials as approved APIs.
Ask the supplier which identified concern the investigation examined, which records were considered, whether a cause was established and what remains unresolved. Request the dated conclusion or current status. Let your technical reviewer decide whether the explanation answers the purchasing concern.
Keep an open question open when supporting records are still awaited. Purchasing correspondence should not turn an unconfirmed explanation into a laboratory finding.
Retesting and resampling need a clear explanation.
FDA distinguishes retesting material from the original homogeneous sample from examining additional units or a newly collected sample. Its guidance rejects repeating tests until a passing result appears and cautions against replacing an unexplained initial OOS result with passing retests. See FDA sections IV.B and V (PDF).
For a proposed additional analysis, request the investigation question, sample reference and connection to the original result. Ask who reviewed the plan and how all resulting reports will be presented. You do not need to design the laboratory's procedure to request a transparent explanation.
Our sample chain-of-custody guide covers sample identity and transfers. The HPLC method guide covers a different question: evidence about the analytical procedure and its run checks.
A replacement report is the start of a question.
You receive a BPC-157 report that does not meet a criterion in your accepted brief. A second report arrives with a different result and a short message saying the issue is resolved. Before changing the order's status, ask how the two sample references connect and which investigation explains the difference.
Request the investigation reference, report history, technical conclusion and the supplier's proposed order action. If a report has been amended, ask the issuer to identify what changed. Keep the explanation beside both versions so your reviewer can see the full sequence.
The useful outcome is a supported decision your team can explain. A newer date or more attractive number does not answer those document questions on its own.
Review the attribute that actually raised the concern.
For KPV, BPC-157 or GHK-Cu, identify the exact material and reported attribute. For GLOW or KLOW, ask which stated component and measurement the result concerns. Unresolved component identities, amounts and blend totals remain questions to resolve; a blend name does not fill in missing specifications.
Separate the tested material from its presentation. A material result does not explain every component of a vial pack or a defined pen-style kit. If the concern concerns packaging instead, identify the affected part and agreed packaging requirement in the order record.
Keep any analytical retesting discussion separate from a retest date or expiry date. Those dates and an investigation of an unexpected result are different review tasks.
Record the answer and the next action.
Have the designated reviewer record which questions are answered, which documents support that view and whether the order can progress under the agreed requirements. If a substitute lot is proposed, request the records for that lot and keep the change visible. Do not silently carry approval from the original lot to a replacement.
Confirm any revised dispatch or receiving arrangements in writing. For an existing order concern, follow our order-concern process; do not send materials back without confirmed instructions. The commercial remedy and technical conclusion each need their own record.
Bring the result and requirement to the same conversation.
Email your organisation, peptide, lot or report reference, agreed requirement, result under review and destination in the USA, Canada or Australia. Include whether your enquiry concerns vials or a defined pen-style kit. Wholesale amounts, pack contents, available records and any separately agreed analysis are confirmed during enquiry.
Wholesale Lab Peptides has warehouses in the USA, Canada, Australia and Hong Kong. Confirm current local availability and dispatch for the selected order. Browse the catalogue, discuss OEM supply or contact sales@wholesalelabpeptides.com.
Discuss a supplier result review